Subsequently after validation in the TCGA-PRAD cohort, parvin alpha (PARVA), ATPase plasma membrane Ca2 + transporting 4 (ATP2B4) and SH3 Domain Binding Glutamate Rich Protein Like (SH3BGRL) were identified as having low expression in prostate cancer and patients with corresponding low expression of these genes had significantly poor PFI (Fig. 2E–J). This evidence concerns the gene PARVA and prostate carcinoma.